尽管第三季度双击败，Verastem Oncology仍有所下降

2025-11-05 01:12

Verastem Oncology (VSTM) is down ~17% in Tuesday trading despite reporting Q3 financial results that beat on both lines.
While it isn't clear what is leading the decline, in the quarter, Verastem saw a significant year-over-year increase in operating costs, along with a $26M cash burn and a relatively high debt-to-equity ratio of 2.35.
Total operating costs increased 40% compared to Q3 2024 to ~$52M.
On the positive front, sales of Verastem's only marketed product, Avmapki Fakzynja co-pack (avutometinib/ defactinib), for ovarian cancer reached ~$11.2M, exceeding company expectations. Q3 was the first full quarter of sales for the medicine.
In the pipeline, upcoming catalysts include plans to begin dose escalation cohorts in combination with chemotherapy for pancreatic ductal adenocarcinoma (PDAC) and with chemotherapy plus an anti-PD-1 for non-small lung cancer Q4 2025 for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor. In 2026 H1, the company anticipates an interim safety and efficacy update on a Phase 1/2a trial of the candidate.

More on Verastem